RAPT Therapeutics (RAPT) is ending its zelnecirnon program after the US Food and Drug Administration put a hold on two clinical trials evaluating the drug as a potential treatment for asthma and atopic dermatitis.

JPMorgan downgraded RAPT Therapeutics to underweight from neutral.

RAPT stock plunged 43% with intraday volume topping 6.11 million versus the daily average of about 299,000.

Sapiens International (SPNS) shares tumbled after the company reported Q3 revenue trailed estimates and lowered 2024 non-GAAP revenue guidance.

The shares slumped 26% as volume topped 559,000 versus the daily average of about 84,000.

AbbVie (ABBV) said its two phase 2 trials assessing emraclidine in adult patients with schizophrenia and acute exacerbation of psychotic symptoms failed to meet their primary goal.

The shares retreated 12% as volume topped 13.1 million versus the daily average of 4.7 million.

Price: 1.65, Change: -1.25, Percent Change: -43.08